Nanoparticle Antibiotic Delivery Systems for Specialized Environments
Legal Citation
Summary of the Inventive Concept
This inventive concept adapts nanoparticles carrying antibiotics for specific, narrow markets or unique operational environments, such as high-security needs, disaster relief, or extreme weather conditions, providing targeted solutions for combating antibiotic resistance.
Background and Problem Solved
The growing antibiotic resistance of harmful microbes has led to a pressing need for innovative drug delivery methods and systems. The original patent's nanoparticles carrying antibiotics addressed this issue, but its limitations in terms of environmental adaptability and accessibility necessitate further development for specialized contexts.
Detailed Description of the Inventive Concept
The new inventive concept involves designing and engineering nanoparticles carrying antibiotics tailored to specific, high-stakes environments. For instance, the system for delivering antibiotics in high-security environments comprises nanoparticles carrying antibiotics, a secure storage container, and a tracking device for monitoring the location and integrity of the nanoparticles. The method for treating infections in extreme weather conditions involves administering nanoparticles carrying antibiotics to a patient, and providing a portable, climate-controlled storage unit for storing the nanoparticles.
Novelty and Inventive Step
The new inventive concept's novelty lies in its adaptation of nanoparticles carrying antibiotics for specialized environments, introducing unique components and operational features that address specific challenges. The inventive step resides in the integration of these components to create targeted solutions that overcome the limitations of the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include variations in nanoparticle composition, surface modification, or loading capacities to suit different environmental conditions. Other implementations could involve integrating nanoparticles with wearable devices, autonomous drones, or telemedicine platforms to enhance accessibility and monitoring.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in various industries, including healthcare, biotechnology, and disaster relief. Target markets may include government agencies, hospitals, and private companies operating in high-security or extreme environments, as well as organizations focused on global health and humanitarian aid.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K9/1075 |
| A | A61 | A61K31/496 |
| A | A61 | A61K47/20 |
| A | A61 | A61K47/552 |
| A | A61 | A61K47/58 |
| A | A61 | A61K47/6907 |
| A | A61 | A61P31/04 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical nanotechnology with a focus on drug delivery systems, specifically antibiotic encapsulation and targeted delivery technologies. Requires expertise in polymer chemistry, pharmaceutical formulation, and nanoscale engineering
Person of Ordinary Skill (PHOSITA) Profile
A researcher or engineer with advanced degrees in pharmaceutical sciences, chemistry, or biomedical engineering, possessing knowledge of nanoparticle synthesis, drug encapsulation techniques, and medical delivery systems
Obviousness Rationale
A person having ordinary skill would recognize that the source patent's nanoparticle antibiotic delivery method provides a foundational technology that can be readily adapted to specialized environments. The PTD's variations represent predictable extensions of the core nanoparticle technology, utilizing standard engineering design choices to address specific contextual challenges in drug delivery. The modifications involve integrating known components and applying standard engineering principles to enhance the utility of the base nanoparticle technology.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,679 |
|---|---|
| Title | Nanoparticles carrying antibiotics |
| Assignee(s) | University of South Florida |